Compare Quest Diagnostics Inc (DGX) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Kohl's Corporation — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Kohl's Corporation trades at $20.36 (market cap $2.28B). The key difference: Quest Diagnostics Inc is far larger — about 11.2× Kohl's Corporation's market cap, and Kohl's Corporation pays the higher dividend (2.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Kohl's Corporation for 48 Days on average.
| DGX | KSS | |
|---|---|---|
Market Cap | $25.48B | $2.28B |
Volume | 941,866 | 4,960,280 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $24.71 |
52-Week Low | $173.49 | $11.72 |
Typical Hold Time | 56 Days | 48 Days |
Enterprise Value | $31.23B | $7.88B |
Dividend Yield | 1.49% | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
Kohl's (KSS) trades at $20.28, up 0.8% with a bullish technical signal despite overbought RSI readings. The stock shows attractive valuation metrics with P/E of 8.63 and P/S of 0.15, while recent earnings beats and raised guidance signal operational improvement. However, revenue has declined for 18 consecutive quarters, presenting a challenging growth environment.
The investment case balances deep value against persistent sales declines. While low valuations and margin improvements support upside potential, sustained revenue weakness and competitive pressures remain key risks. Analyst consensus is mixed with 30% buy ratings but a $15.50 price target below current levels, suggesting cautious optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
